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Abstract
Background: In Iran, co-infections of Plasmodium vivax and Plasmodium falciparum are common and
P. vivax infections are often exposed to sulphadoxine-pyrimethamine (SP). In the present study, the
frequency distribution of mutations associated to SP resistance was investigated in pvdhfr and
pvdhps genes from field isolates.
Methods: Clinical isolates of P. vivax were collected in two different malaria endemic regions in
northern and south-eastern Iran, between 2001 and 2006. All 189 collected isolates were analysed
for SNP/haplotypes at positions 13, 33, 57, 58, 61, 117 and 173 of the pvdhfr and 383 and 553 of
pvdhps genes using nested PCR-RFLP methods
Results: All 189 examined isolates were found to carry wild-type amino acids at positions 13, 33,
61 and 173, while 57L and 58R and 117N mutations in pure form was detected among 1.1%, 17.5%
and 26% examined samples, respectively, with no polymorphisms in different loci of dhps genes.
Based on size polymorphism of pvdhfr  genes at repeat region, among northern isolates, the
frequency distribution for type A and B were 2.2% and 97.8% respectively. However, in southern
samples the prevalence of type A, B and C were 7%, 89.5% and 7.7%, respectively. Mixed genotype
infections (type B and C) were detected in only 4.2% (6/143) of southern, but in none of the
northern isolates. The combination of pvdhfr and pvdhps haplotypes among all 189 samples
demonstrated six distinct haplotypes. The two most prevalent haplotypes among all examined
samples were I13P33F57S58T61S117I173/A383A553 (65.6%) and I13P33F57S58T61N117I173 (16.4%). Two
other alleles with one point mutation I13P33F57R58T61S117I173/A383A553  and two mutations
I13P33F57R58T61N117I173/A383A553 accounted for 7.4% and 9.5% of the total isolates.
Conclusion: The present molecular data provide important information for making decisions on
population based drug use in Iran. In addition, since October 2005, with more availability of SP as
first-line treatment, P. vivax isolates are more exposed to SP and the selection or spread of resistant
pvdhfr and pvdhps alleles might increase in the near future in this region.
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Background
Plasmodium vivax remains the most widespread malaria
parasite in areas outside of Africa [1] and chloroquine
(CQ) remains the first-line treatment for vivax malaria in
most endemic regions. In recent years, chloroquine-resist-
ant P. vivax parasites have been reported in several loca-
tions, with high level resistance confirmed in parts of
Thailand, Indonesia and New Guinea and in Central
America [2-7]. In those countries, where sulfadoxine/
pyrimethamine (SP) has been used extensively, high
grade antifolate resistance has also emerged in P. vivax
populations [8-13].
Unfortunately, resistance develops relatively quickly,
when SP is widely used. Molecular and epidemiological
studies of both Plasmodium falciparum and P. vivax have
revealed that the dihyrofolate reductase (DHFR) and
dihydropteroate synthase (DHFR) enzymes are the thera-
peutic targets of SP [10-17]. As a result, resistance to SP is
determined by specific point mutations in the parasite
dhfr and dhps genes. These mutations cause alterations of
key amino acid residues in the active sites of these
enzymes, which reduce the affinity of the enzyme for the
drug [15,18-25]. Therefore, detection of these mutations
in wild isolates has proved valuable in the mapping and
monitoring of resistance for guiding malaria control
measures.
Vivax infections are not often treated with SP, but P. vivax
isolates are exposed to SP because mixed infections are
common in Asia and South America [26-29] and are often
mis-diagnosed. As continuous in vitro culture of P. vivax
remains unavailable, and it is difficult to monitor the sus-
ceptibility of P. vivax to anti-malarial drugs by in vitro tests
[30,31], the association between the various pvdhfr point
mutations and resistance to pyrimethamine relies on epi-
demiological and clinical investigations. Different studies
showed that in areas where there is a long history of exten-
sive SP use, mutant alleles of pvdhfr gene are prevalent;
however wild type pvdhfr has been found more commonly
in areas with limited use of SP [10,12,13,17]. So far, 20
non-synonymous mutations have been described in pvd-
hfr, [31] and different studies of P. vivax parasites in differ-
ent malaria endemic areas, such as Thailand and India,
showed that mutations at pvdhfr codons 57, 58, 61, 117
and 173, [13,32] were found to be involved in clinical
antifolate resistance [12,31]. Five mutations have already
been identified in pvdhps gene, at codons 382, 383, 512,
553, and 585.
Iran is located in the Middle East and, in this region, P.
vivax  is the most prevalent malaria parasite species,
responsible for 80 to 90% of malaria cases. The disease is
endemic in the south-east bordering with Pakistan and
Afghanistan, but it re-emerged in the north of the country
after a 20-year interruption of transmission [33]. In Iran,
CQ has been used as the first line anti-malarial treatment
and SP was used as second-line treatment [34] for uncom-
plicated  P. falciparum infection. Furthermore, while in
vitro  studies have reported SP resistance since 1993
[35,36], in vivo resistance of P. falciparum to SP is not yet
common in these areas. With the spread of chloroquine
resistance in P. falciparum, the Center for Diseases Man-
agement and Control (CDMC), decided in 2005 to revise
its treatment policy and SP in combination with CQ has
been recommended as the first-line anti-malarial treat-
ment, with artemether-lumefantrine (Co-Artem®), as sec-
ond-line [34]. Although SP may remain the treatment of
choice for uncomplicated malaria, the high rates of treat-
ment failures with CQ [34] and, therefore, inadequate
efficacy of treatment with the SP/CQ combination, the
CDMC decided in 2007 to revise its treatment policy
again and SP/CQ was replaced with SP/artemisinin as the
first-line recommendation for falciparum malaria. CQ
remains the first choice for treatment of P. vivax mono-
infections and resistance to either CQ or SP has not yet
been recorded in Iran. In addition, in this area P. vivax co-
exists with P. falciparum [26] but the correct diagnosis of
mixed infections is not easy based on microscopic exami-
nation of blood films, and the clinical symptoms caused
by the two species cannot be differentiated. As a result, P.
vivax may often be treated with SP because of mixed infec-
tions and inaccurate diagnosis.
The pvdhfr and pvdhps genotype might be associated with
treatment failure in individual vivax malaria patients, and
while data on the genotypes of these two genes are availa-
ble from Thailand, the Indian subcontinent and the Indo-
nesian archipelago, such data are lacking in many regions,
most notably Central and South America and the Middle
East, with only a few isolates from those regions having
been assessed for mutations in dhfr.
Methods
Study sites and P. vivax clinical isolates
In this study, 189 P. vivax clinical isolates were collected
between March 2001 and March 2006, from P. vivax-
infected patients, aged from one to > 60 years, living either
in the tropical south-eastern region (Chabahar district in
Sistan and Baluchistan) (n = 143), or in area of resurgent
malaria (Pars Abad in Ardebil province) in the temperate
northern endemic area (n = 46). The most prevalent para-
site species in the temperate northern region is P. vivax,
with Anopheles maculipennis and Anopheles sacharovi as the
main vectors, and Anopheles superpictus and Anopheles hyr-
canus  as the secondary vectors. In the south-eastern
region, transmission is year-round with two peaks, the
first in May to August with P. vivax as the predominant
species and the second peak from October to November
when both P. falciparum and P. vivax infections are equallyMalaria Journal 2009, 8:20 http://www.malariajournal.com/content/8/1/20
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recorded. The main mosquito vectors in the south-eastern
region are Anopheles stephensi, Anopheles culicifacies, Anoph-
eles fluviatilis and Anopheles pulcherrimus.
All subjects had slide and PCR-proven infection by P.
vivax. None of the subjects received SP therapy and infec-
tions were treated with chloroquine. In both study areas
the patients have access to anti-malarial drugs through
local health centers.
Informed consent was obtained from patients or parents
of patients before inclusion in the study. The study was
reviewed by, and received Ethical Clearance from Institut
Pasteur of Iran. Blood samples were collected in tubes
containing EDTA, stored at 4°C and then transported to
the main laboratory in Tehran.
Parasite genomic DNA extraction
Parasite DNA was extracted from 250 μl infected whole
blood by phenol/phenol-chloroform extraction and etha-
nol precipitation as described previously [37]. The DNA
was dissolved in 30 μl TE buffer (10 mM Tris-HCL pH 8.0,
0.1 mM EDTA). For the detection of point mutations at
residues 13, 33, 57, 58, 61, 117 and 173, the previously
described PCR-RFLP protocols were used with some mod-
ifications [12,13,38].
Primary amplification of pvdhfr
In the first reaction, the entire P. vivax dhfr-ts gene was
amplified by the primers VDT-OF: ATGGAGGACCTTTCA-
GATGTATTTGACATT and VDT-OR: GGCGGCCATCTC-
CATGGTTATTTTATCGTG [13]. The cycling conditions for
the nest-1 reaction was as follows: 95°C for 5 min, 25
cycles of 64°C for 2 min, 72°C for 2 min, 94°C for 1 min
followed by 64°C for 2 min and 72°C for 15 min.
PCR amplification of positions 13, 33, 58, and 61
One μl product of the first reaction was then used in sec-
ond round of amplification using the following primers
for positions 13, 33, 58, and 61:
VDFN13F: GACCTTTCAGATGTATTTGACATTTACGGC
VDFN13R: GGTACCTCTCCCTCTTCCACTTTAGCTTCT
The cycling conditions for the nest-2 reaction was as fol-
lows: 95°C for 5 min, 25 cycles of 66°C for 2 min, 72°C
for 2 min, 94°C for 1 min followed by 66°C for 2 min
and 72°C for 15 min.
RFLP
To detect mutation at position 13L, 10 μl of the PCR prod-
ucts were digested with 10 U HaeIII enzyme (Roche, Ger-
many) for 1 h at 37°C in a total volume of 20 μl (232 bp
= 32 bp + 200 bp). To detect mutations at residue P33L
and S58R, 10 μl of the PCR products were digested with
10 U Cfr42I (SacII) (Fermentase, Vilnius, Lithuania) and
AluI (Roche, Germany) for 4 h at 37°C in a total volume
of 20 μl (232 bp = 94 bp + 138 bp for P33 and 232 bp =
25 bp + 207 bp for 58R, 232 bp = 25 bp+40 bp+167 bp
for wild type S58), respectively. Mutation at residue 61 M
was detected by digestion of 10 μl of the PCR products
with 10 U Tsp45I  (New England Biolab, Beverly, MA,
USA) for 4 h at 37°C in a total volume of 20 μl (232 bp =
32 bp + 200 bp).
PCR amplification of positions 57 and 173
The product of first reaction was also amplified with oli-
gonucleotide pair:
VDT-OF: ATGGAGGACCTTTCAGATGTATTTGACATT
VDFNR: TCACACGGGTAGGCGCCGTTGATCCTCGTG
to amplify positions 57 and 173. The cycling conditions
for the nest-2 reaction was as follows: 95°C for 5 min, 25
cycles of 66°C for 2 min, 72°C for 2 min, 94°C for 1 min
followed by 66°C for 2 min and 72°C for 15 min. It
should be noted that because of presence of repeat regions
that amplify the above-mentioned primers, there are size
variations among the amplified PCR products, which
affect the size of digested products. In the present study,
the size of the digested PCR products, which is reported in
the following RFLP section, is based on pvdhfr Accession
no: X98123.
RFLP
To detect mutation at residue F57, 10 μl of the PCR prod-
ucts were digested with 10 U XmnI: (New England Biolab,
Beverly, MA, USA) for 4 h at 37°C in a total volume of 20
μl (608 bp = 166 bp + 442 bp). Mutation at residue I173L
was detected by digestion of 10 μl of the PCR products
with 10 U Eco130I (StyI) (Fermentase, Vilnius, Lithuania)
for 4 h at 37°C in a total volume of 20 μl (wild type I173:
608 bp = 136 bp + 472 bp and mutant type 173L: 608 bp
= 73 bp + 97 bp + 438 bp).
PCR amplification of positions 57 and 117
One μl product of first reaction was also amplified with
primers:
VDNF57:CATGGAAATGCAACTCCGTCGATATGATGT
VDF-NR:TCACACGGGTAGGCGCCGTTGATCCTCGTG
The cycling conditions for the this reaction was 95°C for
5 min, 25 cycles of 66°C for 2 min, 72°C for 2 min, 94°C
for 1 min followed by 66°C for 2 min and 72°C for 15
min.Malaria Journal 2009, 8:20 http://www.malariajournal.com/content/8/1/20
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RFLP
To detect mutation at residue 57I, 10 μl of the PCR prod-
ucts were digested with 10 U BsrGI (New England Biolab,
Beverly, MA, USA) for 4 h at 37°C in a total volume of 20
μl (472 bp = 28 bp + 444 bp). To detect mutation at resi-
due S117N/T, 10 μl of the PCR products (472 bp) were
digested with 10 U PvuII (New England Biolab, Beverly,
MA, USA) (S117, 214 bp + 258 bp), for 4 h at 37°C and
BsrI (New England Biolab, Beverly, MA, USA (117N, 219
bp + 253 bp), BstNI (New England Biolab, Beverly, MA,
USA) (117T, 215 bp + 257 bp) for 1 h at 65°C in a total
volume of 20 μl. All amplifications were carried out in a
final volume of 25 μl, which included 1 μl of template
from either genomic DNA or the primary reaction. The
primers were used at a final concentration of 250 nM and
the reaction mixture contained 10 mM Tris-HCL (pH 8.3),
50 mM KCl, 2 mM MgCl2, each of the four deoxynucle-
otide triphosphates at a concentration of 125 μM, and 0.2
U of Taq polymerase (Invitrogen, Carlsbad, CA). The
DNA fragments obtained following PCR amplification or
RFLP analysis were electrophoresed on 2.5% (Invitrogen,
Carlsbad, CA) and 3% Metaphor (Invitrogen, Carlsbad,
CA) agarose gels, respectively. All digested products of
RFLP were subjected to electrophoresis on 3% MetaPhor
agarose gels.
Analysis of pvdhfr gene at repeat region
This region was amplified using 1 μl of primary reaction
with primers:
VDFN2F: CGGTGACGACCTACGTGGATGAGTCAAAGT
VDFN2R: TAGCGTCTTGGAAAGCACGACGTTGATTCT as
described previously [12]. The cycling conditions for the
this reaction was 95°C for 5 min, 25 cycles of 66°C for 2
min, 72°C for 2 min, 94°C for 1 min followed by 66°C
for 2 min and 72°C for 15 min. The DNA fragments
obtained following PCR amplification were analysed fol-
lowing electrophoresis on 3% Metaphor agarose gels.
Amplification of pvdhps
The pvdhps  gene was amplified from genomic DNA by
nested PCR. The primers used in the first and second
round PCRs were described previously [38]. In the first
reaction pvdhps was amplified with primers:
VDHPS-OF: ATTCCAGAGTATAAGCACAGCACATTTGAG
VDHPS-OR: CTAAGGTTGATGTATCCTTGTGAGCACATC
The second amplification was performed with the primers
for detection of 383 mutation:
VDHPS-NF: AATGGCAAGTGATGGGGCGAGCGT-
GATTGA
VDHPS-NR: CAGTCTGCACTCCCCGAT-
GGCCGCGCCACC
for detection of the 553 mutations the oligonuclotide
primers
VDHPS-553OF: TTCTCTTTGATGTCGGCCTGGGGTT-
GGCCA
VDHPS-NR: CAGTCTGCACTCCCCGATGGCCGCGCCA
CC were used.
The cycling conditions for the nest-1 PCR reaction was as
follows: 95°C for 5 min, 25 cycles of 58°C for 2 min,
72°C for 2 min, 94°C for 1 min followed by 58°C for 2
min and 72°C for 15 min and for nest-2 PCR was: 95°C
for 5 min, 25 cycles of 50°C for 2 min, 72°C for 2 min,
94°C for 1 min followed by 50°C (for VDHPS-553OF
and VDHPS-NR 50°C) for 2 min and 72°C for 15 min.
RFLP
To detect mutation at residue A383G, 10 μl of the PCR
products were digested with 10 U MspI (HpaII) (Fermen-
tase, Vilnius, Lithuania) (mutant 383G, 703 bp = 48 bp +
655 bp) and MscI  (New England Biolab, Beverly, MA,
USA) (wild A553, 170 bp = 27 bp + 143 bp) for 4 h at
37°C in a total volume of 20 μl.
Results
Distribution of mutations in pvdhfr and pvdhps
All 189 isolates from north and south were analysed for
SNP/haplotypes at positions 13, 33, 57, 58, 61, 117 and
173 of the pvdhfr and 383 and 553 of pvdhps genes using
PCR-RFLP methods [12,13,38]. In pvdhfr, polymorphisms
at positions 57L, 58R and 117N have been found in 1.4%,
21.7% and 30% of southern isolates, respectively (Table
1). Among northern isolates mutations at 58R and 117N
were found in 4.4% and 13% of the studied isolates,
respectively (Table 1).
In total, all 189 examined isolates were found to carry
wild-type amino acids at positions 13, 33, 61 and 173,
while 57L and 58R and 117N mutations in pure form was
detected among 1.1%, 17.5% and 26% examined sam-
ples, respectively (Table 1). In the case of pvdhps gene, pol-
ymorphisms in different loci of dhps (A383G and A553G)
were investigated and no mutations were detected at all in
the examined samples.
Size polymorphism of pvdhfr at repeat region
In this investigation all three types A, B and C [12] were
found among southern isolates, but only types A and B
were detected among northern isolates. The frequency dis-
tribution for type A and B were 2.2% (1/46) and 97.8%
(45/46) among northern isolates, respectively. However,Malaria Journal 2009, 8:20 http://www.malariajournal.com/content/8/1/20
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for southern samples the prevalence of the type A, B and
C were 7%, 89.5% and 7.7%, respectively. Mixed geno-
type infections (type B and C) were detected in only 4.2%
(6/143) of southern, but not in northern isolates.
Distribution of pvdhfr and pvdhps haplotypes in Iran
The combination of pvdhfr and pvdhps haplotypes among
all 189 samples in this study demonstrated six distinct
haplotypes (Figure 1). The two most prevalent haplotypes
among all examined samples were I13P33F57S58T61S117I173/
A383A553  (65.6%) and I13P33F57S58T61N117I173/A383A553
(16.4%). Two other alleles with one point mutation at
position I13P33F57R58T61S117I173/A383A553 and two muta-
tions at position 58R and 117N (I13P33F57R58T61N117I173/
A383A553) accounted for 7.4% and 9.5% of the total iso-
lates. This double mutant haplotype was the most fre-
quently mutated haplotype observed among Iranian
samples. Regarding these nine SNPs in pvdhfr and pvdhps
genes, significant increasing in the prevalence of double
mutated haplotypes (I13P33F57R58T61N117I173/A383A553)
was observed in collected samples in year 2006 compare
to 2001 (P > 0.005) (Table 2). In addition, the majority of
isolates from north and also south were wild haplotype
and I13P33L57R58T61S117I173/A383A553 (0.7%) mutant hap-
lotype was only detected among southern but northern
isolates (Table 1).
Discussion
In regions where P. falciparum and P. vivax co-exist, it is
crucial to identify effective treatment regimens that work
against both parasite species. In malaria-endemic areas
co-infection of P. vivax and P. falciparum is common and
the long history of SP use has exposed P. vivax to this drug
for decades. In the present study, the SP resistance-associ-
ated genes, pvdhfr and pvdhps, were analysed in samples
collected (prior to introduction of SP as first-line anti-
malarial), from re-emerged area in north and endemic
region in south where both CQ and SP (in combination
with primaquine) were used for treatment. In the south,
although CQ still remains effective against P. vivax infec-
tion, the in vivo work in 2005 [39] showed that parasite
clearance time increased compared to 2001 in Sistan and
Baluchistan province, indicating that this could be an
early sign of reduced susceptibility of the parasites to CQ.
Therefore, effective alternative drug against P. vivax resist-
ance to CQ might be needed. In this investigation, four
and six distinct haplotypes of pvdhfr and only wildtype of
pvdhps were detected among northern and southern iso-
lates, respectively. The double mutant
I13P33F57R58T61N117I173/A383A553 was the second frequent
haplotype in our examined isolates. This is the first time
that mutations at associated genes to SP resistance have
been described in a large number of P. vivax isolates from
the Middle East.
Mutations in pvdhfr, including 58R and 117N, have been
implicated in in vivo pyrimethamine resistance and seem
to arise first under drug pressure. The 58R was found in
17.5% of all examined isolates alone and in combination
with 117N in 9.5%, despite the fact that SP had never
been used as a first-line treatment for falciparum malaria
before October 2005. The work carried out by Tahar and
colleagues [40] showed that the 58R/117N mutant had a
lower affinity for pyrimethamine and cycloguanil than
did the wild type enzyme. In addition, Leartsakulpanich et
al  screened pyrimethamine resistance-associated genes
Table 1: The frequency distribution of SNPs combinations of pvdhfr and pvdhps alleles associated with sulphadoxine/pyrimethamine in 
Plasmodium vivax isolates from north and southeastern, Iran
Pvdhps pvdhfr
A383G A553G I13L P33L F57I/L S58R T61M S117T/N I173L South (%)
n = 143
North (%)
n = 46
Total (%)
n = 189
A A I P F S T S I 85 (59.4%) 39 (84.8%) 124 (65.6%)
AA I PF S TN I 26 (18.2%) 5 (10.8%) 31 (16.4%)
AA I PF R T S I 13 (9.1%) 1 (2.2%) 14 (7.4%)
AA I PF R T N I 17 (11.9%) 1 (2.2%) 18 (9.6%)
AA I PL S T S I 1 (0.7%) - 1 (0.5%)
AA I PLR T S I 1 (0.7%) - 1 (0.5%)
-- - - L = 1.1% R = 17.5% - N = 26% -Malaria Journal 2009, 8:20 http://www.malariajournal.com/content/8/1/20
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and found that the 117N, 58R/117N, 58R and 173L
mutant enzymes were more resistance to this drug than
the wild type [41]. The similar work by Hastings and col-
leagues confirmed these results [11]. Regarding the clini-
cal efficacy of SP against P. vivax, several workers
concluded that the clinical response to SP depends on pvd-
hfr and pvdhps genotype [11,12,17]. They also showed that
those patients who harboured triple and quadruple
mutant parasites (57L/58R/61M/117T) compared with
those who harboured wild type parasites were signifi-
cantly associated more likely to SP treatment failure
[11,12,17]. In addition, treatment failure was more fre-
quently associated with multiple mutations in dhfr and
dhps  [38]. This correlation between two genes also
reported for P. falciparum, as parasite carried wild type
alleles of dhfr and dhps, the patient is likely to have an ade-
quate clinical response to SP, but when the parasite carries
mutant alleles of both genes, clinical effectiveness is com-
promised [42-48]. Although none of the P. vivax isolates
have been tested in this study for their clinical response to
SP, triple and quadruple mutant types, found in Thailand,
India, and in Indonesia have previously been shown to be
associated with a high risk of SP treatment failure
[11,12,17].
Frequency distribution of the combination pvdhfr/pvdhps haplotypes obtained from 189 isolates collected in Ardebil province in  north and Sistan and Baluchistan province in southeastern of Iran Figure 1
Frequency distribution of the combination pvdhfr/pvdhps haplotypes obtained from 189 isolates collected in 
Ardebil province in north and Sistan and Baluchistan province in southeastern of Iran. The haplotype 
I13P33F57S58T61S117I173/A383A553 was the most prevalent among northern (84.8%) and southern (59.4%) P. vivax isolates. All six 
haplotypes are indicated as A to F in the figure. Mutated amino acids are boldfaced. A) I13P33F57S58T61S117I173/A383A553. B) 
I13P33F57S58T61N117I173/A383A553. C) I13P33F57R58T61S117I173/A383A553. D) I13P33F57R58T61N117I173/A383A553. E) 
I13P33L57S58T61S117I173/A383A553. F) I13P33L57R58T61S117I173/A383A553.Malaria Journal 2009, 8:20 http://www.malariajournal.com/content/8/1/20
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The frequency distribution of pvdhfr mutant haplotypes
was significantly higher in the endemic southern regions
than re-emerged northern region (Pars-Abad, Ardebile).
This might be caused by the level of disease endemicity in
the south and longer usage of SP for treatment of P. falci-
parum infections. In other words, SP never used in north
for treatment of malaria disease as any P. falciparum infec-
tions was not detected by microscopy method; therefore
no SP pressure might be responsible for prevalence of
mutant alleles of dhfr in this region. In fact, the limited
diversity of pvdhfr mutant, particularly double mutants in
northern compare to southern isolates may also be an
indication for a founder effect linked to the introduction
of malaria from Azerbaijan and Armenia to northern part
of Iran. The presence of I13P33L57R58T61S117I173/A383A553
haplotype only among southern isolates may be related to
human migration between Iran and Pakistan, resulting to
introduction of such haplotypes from the Indian subcon-
tinent, where it is prevalent [31].
In the present study, the most common haplotypes of pvd-
hfr were wild type and double mutant (58R and 117N);
but triple and quadruple mutants were not detected
among examined isolates. In contrast, molecular analysis
of pvdhfr among Indian field isolates showed 14 haplo-
types from wild type to quadruple mutant genotype, and
wild type and double mutant were still the most common
[31]. Since 2005, based on the national drug policy, the
anti-malarial treatment in Iran has changed and the SP
became the first choice drug for treatment. With more
availability of SP, there is a risk of a changing pattern of
resistance of both P. falciparum and P. vivax to SP, as this
closely follows the intensity with which SP has been used
[31]. In addition, other antifolates such as co-trimoxazole
that are routinely used against urinary tract infections and
chronic bronchitis in the region could add to the overall
antifolate pressure in Iran.
Conclusion
The present molecular data provide important informa-
tion for making decisions on population based drug use
in Iran. In addition, previous study showed that in regions
where the wild type or single mutated pvdhfr alleles are
prevalent, SP could be a useful therapy [31] for the asexual
erythrocytic stages of vivax in areas where CQ treatment
failure has been reported.
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